Abstract: A method of treating a subject having cancer, particularly a multidrug resistance cancer, which comprises administering to the subject at least one chemotherapeutic agent and at least one 3-aryloxy-3-phenylpropylamine and pharmaceutical compositions and kits for implementing the method.

Abstract: Lipidated glycosaminoglycan particles are prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaiminoglycan with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs for use in the treatment of pathological conditions in an animal.

Abstract: A method of treating a subject having cancer, particularly a multidrug resistance cancer, which comprises administering to the subject at least one chemotherapeutic agent and at least one 3-aryloxy-3-phenylpropylamine and pharmaceutical compositions and kits for implementing the method.

Abstract: The present invention provides formulations of insulin or insulin analogs encapsulated in a liposome, and methods of producing such formulations. The invention further provides methods of treating hyperglycemia and related disorders by administering a formulation of the invention.

Abstract: A pharmaceutical composition which comprises a chemotherapeutically effective amount of one or more chemotherapeutic agent(s), being entrapped in a drug carrier, and a chemosensitizing effective amount of one or more chemosensitizing agent(s) and/or a chemoprotecting effective amount of one or more chemoprotecting agent(s) and methods of using same in cancer therapy.

Abstract: A method of chemosensitization which comprises administering at least one chemotherapeutic agent and at least one 3-aryloxy-3-phenylpropylamine to a subject in need thereof.

Abstract: A method of chemosensitization which comprises administering at least one chemotherapeutic agent and at least one 3-aryloxy-3-phenylpropylamine to a subject in need thereof.

Abstract: The present invention provides formulations of insulin or insulin analogs encapsulated in a liposome, and methods of producing such formulations. The invention further provides methods of treating hyperglycemia and related disorders by administering a formulation of the invention.

Abstract: The cationic liposomal formulations of the present invention provide nucleic acid and gene product delivery devices having a glycosaminoglycan covalently attached to the liposome surface. The glycosaminoglycan can be any glycosaminoglycan, including but not limited to hyaluronic acid, the chondroitin sulfates, keratan sulfate, chitin and heparin. Preferably, the glycosaminoglycan is hyaluronic acid. The present invention also provides methods of preparing the nucleic acid-liposome formulations.

Abstract: Recognizing substances, including epidermal growth factor, gelatin, collagen and hyaluronic acid, have been covalently bound to liposomal surfaces and utilized to attach liposomes onto a cellular or an extracellular matrix (ECM) target site. These "bioadhesive" liposomes offer several advantages including the mutual protection of both the drug and biological environment; an increase in drug bioavailability and retention at the target site; and improved adherence or adhesion to the designated target site.

Abstract: Recognizing substances, including epidermal growth factor, gelatin, collagen and hyaluronic acid, have been covalently bound to liposomal surfaces and utilized to attach liposomes onto a cellular or an extracellular matrix (ECM) target site. These "bioadhesive" liposomes offer several advantages including the mutual protection of both the drug and biological environment; an increase in drug bioavailability and retention at the target site; and improved adherence or adhesion to the designated target site.

Abstract: Methodologies have been developed and certain recognizing substances and crosslinking reagents have been identified to modify liposomes. Crosslinking reagents link residues on the liposomal surface to the residues offered by certain recognizing substances. The crosslinking reagents include glutaraldehyde (GAD) and a water soluble carbodiimide, preferably, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). The recognizing substances include gelatin, collagen, and hyaluronic acid (HA). Following these methodologies, recognizing substances can be utilized as an adhesive or glue to attach the liposomes onto a target area. These "bioadhesive" liposomes offer potential advantages as a microscopic drug delivery system.